complement therapeutics Archives -

Apellis’ chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may

Longer-term data raise prospects for Apellis’ pegcetacoplan

https://pharmaphorum.com/news/longer-term-data-raise-prospects-for-apellis-pegcetacoplan/

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying

Novartis’ iptacopan hits the mark in rare kidney disease C3G

https://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/

Apellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major

Apellis reports mixed data with eye drug, but plans to file anyway

https://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/

It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

https://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris,

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

https://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/

November 13-15, 2019 | Boston, MA

3rd Annual Complement-based Drug Development Summit 2019

https://pharmaphorum.com/events/3rd-annual-complement-based-drug-development-summit-2019/

complement therapeutics